Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PGAM1 | P18669 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11577441 | 0.81 | ALDH1A1 (0.68) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL7435273 | 0.81 | BCL2 (0.63) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL23199010 | 0.81 | MAPT (0.69) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL14379281 | 0.80 | MAPT (0.51) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL18601894 | 0.79 | RAB9A (0.62) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL1609981 | 0.78 | GAA (0.41) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL11515026 | 0.77 | ALDH1A1 (0.56) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL16227229 | 0.76 | MAPT (0.65) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL31237408 | 0.76 | MAPT (0.65) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL23198991 | 0.76 | EPHX2 (0.65) | NPC1RAB9AMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020037931-A1 | Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them | PORTELA & C.A., S.A. (PT) | 2002-03-28 | — | — | US | disclosed |
| EP-1167341-A1 | Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them | Portela & Ca., S.A. (PT) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001098250-A1 | SUBSTITUTED NITRATED CATECHOLS, THEIR USE IN THE TREATMENT OF SOME CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PORTELA & CA SA (PT) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037931-A1 | Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them | SLC6A2, COMT, SLC6A3 | NPC1 930/4885RAB9A 3311/4885MAPT 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.